SLN
Silence Therapeutics plc
There isn't enough reported data to score SLN yet.
SLN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Unavailable |
SLN's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
SLN PE Valuation
SLN has no meaningful PE right now: it lost money over the past year.
SLN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect SLN's losses to shrink, with revenue declining.
SLN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$2.61 | +$1.98 |
| Q3 2024 | -$5.24 | -$0.57 |
| Q2 2024 | -$3.84 | +$0.83 |
| Q1 2024 | -$3.68 | +$1.43 |
| Q4 2023 | -$4.59 | +$0.44 |
| Q3 2023 | -$4.67 | -$0.72 |
| Q2 2023 | -$4.67 | -$1.16 |
| Q1 2023 | -$5.11 | -$2.68 |
SLN lost $2.61 per share over the past year, a smaller loss than the year before.
SLN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $422K | +197% |
| Q4 2025 | $34K | -100% |
| Q3 2025 | $159K | -90% |
| Q2 2025 | $224K | -72% |
| Q1 2025 | $142K | -99% |
| Q4 2024 | $32.4M | +1059% |
| Q3 2024 | $1.5M | -59% |
| Q2 2024 | $795.5K | -93% |
SLN's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -3729% | +16277 points |
| Q4 2025 | -36650% | -36637 points |
| Q3 2025 | -16506% | -14532 points |
| Q2 2025 | -10698% | -7634 points |
| Q1 2025 | -20006% | -19971 points |
| Q4 2024 | -13% | +621 points |
| Q3 2024 | -1973% | -1520 points |
| Q2 2024 | -3064% | -2938 points |
SLN's operating margin was −3729% last quarter, up 16277 points from the same quarter a year ago.
SLN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $1.5M | +$23.4M |
| Q1 2026 | -$15.6M | -$3.3M |
| Q4 2025 | -$17.3M | +$15.9M |
| Q3 2025 | -$10.9M | +$15.3M |
| Q2 2025 | -$21.8M | -$14.5M |
| Q1 2025 | -$12.3M | -$150.7K |
| Q4 2024 | -$33.1M | -$17.4M |
| Q3 2024 | -$26.2M | -$19.7M |
SLN has burned cash in most quarters: −$42M over the past year, against −$94M the year before.
SLN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -136K shares |
| 1 year | +18% | +2.3M shares |
| 3 years | -48% | -14.1M shares |
| 5 years | -41% | -10.8M shares |
SLN has 16M diluted shares, up 18% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
SLN hasn't bought back shares in the past year.
SLN Net Leverage
SLN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SLN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.8 | Overbought |
| Stochastic | 99.1 | Overbought |
SLN's weekly RSI is 72 (overbought) and its Stochastic is 99 (overbought).
SLN PE vs Healthcare Sector
SLN has no meaningful PE right now: it lost money over the past year.
SLN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.9 | 33% above |
| 20 week MA | $13.2 | 51% above |
| 50 week MA | $9.00 | 120% above |
| 100 week MA | $7.15 | 177% above |
| 200 week MA | $10.6 | 88% above |
SLN has climbed back above all five of its weekly moving averages, and it's now 88% above its 200-week average.
SLN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.5 | $20.0 | +2.6% |
| 2021 | $20.0 | $23.4 | +17% |
| 2022 | $23.4 | $14.2 | -39% |
| 2023 | $14.2 | $17.4 | +23% |
| 2024 | $17.4 | $7.10 | -59% |
| 2025 | $7.10 | $6.20 | -13% |
| 2026 YTD | $6.20 | $19.8 | +219% |
SLN is up 219% so far in 2026, after finishing lower in three of the previous six years.